Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.52 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355117 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29398212 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL30896049 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL1486287 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL1486214 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL118209 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL30896048 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL6038102 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL1564185 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29398684 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116773724-A | High performance liquid chromatography for simultaneously detecting fluorenylmethoxycarbonyl-L-isoleucine and four impurity amino acids thereof | 成都郑源生化科技有限公司 | 2023-09-19 | — | — | CN | claimed |
| CN-116606348-A | Self-assembled supermolecule nano material responding to AXL kinase and preparation method and application thereof | 东南大学 | 2023-08-18 | — | — | CN | claimed |
| CN-116425827-A | Short peptide Fmoc-L-Ile-Aib-OH and preparation method thereof | 成都郑源生化科技有限公司 | 2023-07-14 | — | — | CN | claimed |
| CN-112430588-B | Short peptide for resisting novel coronavirus infection and preparation method and application thereof | 中国人民解放军陆军军医大学 | 2022-12-30 | — | — | CN | claimed |
| CN-113072620-B | PD-1 targeting peptide with analgesic activity, and synthesis method and application thereof | 南通大学 | 2022-07-05 | — | — | CN | claimed |
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | claimed |
| CN-113072620-A | PD-1 targeting peptide with analgesic activity, and synthesis method and application thereof | 南通大学 | 2021-07-06 | — | — | CN | claimed |
| CN-112430588-A | Short peptide for resisting novel coronavirus infection and preparation method and application thereof | 中国人民解放军陆军军医大学 | 2021-03-02 | — | — | CN | claimed |
| CN-112110834-A | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2020-12-22 | — | — | CN | claimed |
| CN-105777866-A | Anti-hypertension bioactive peptide and preparing method thereof | 南京大学 | 2016-07-20 | — | — | CN | claimed |
| CN-102786579-B | Antihypertensive active peptide VIP | UNIV SHANGHAI JIAOTONG | 2014-07-09 | — | — | CN | claimed |
| CN-102702343-A | Method for synthesizing tesamorelin through solid phases | GL BIOCHEM SHANGHAI CO LTD | 2012-10-03 | — | — | CN | claimed |
| CN-102443048-A | Synthetic method of 5-membered cyclopeptide | JIANGSU YEW PHARMACEUTICAL CO LTD | 2012-05-09 | — | — | CN | claimed |
| CN-100590068-C | Method for preparing primary amine carbon nano tube | UNIV TONGJI | 2010-02-17 | — | — | CN | claimed |
| CN-101177259-A | Method for preparing primary amine carbon nano tube | UNIV TONGJI (CN) | 2008-05-14 | — | — | CN | claimed |
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| WO-1997019681-A1 | PERFLUOROALKYL SUBSTITUTED METALLO-BETA-LACTAMASE INHIBITORS AND METHOD FOR THE PREPARATION OF TRIFLUOROMETHYLKETONE DERIVATIVES | ISIS INNOVATION LIMITED (GB) | 1997-06-05 | — | — | WO | disclosed |
| EP-0346108-A2 | Anti-infective nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | CETP, LIPA, MTTP | CASP3 1489/4885MDM4 3741/4885TP53 1141/4885 |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | CETP, SLC43A1, SLC27A1 | CASP3 2158/4885MDM4 884/4885TP53 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.